FITZGERALD EDWARD M 4

What Happened
Edward M. Fitzgerald, a director of Parabilis Medicines, was granted a derivative award on 2026-06-09 covering 20,215 shares. The grant is reported at $0.00 per share (no immediate cash value) and is recorded as a derivative/award rather than an open-market purchase or sale. This is a compensation/award transaction rather than a stock sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (appears timely).
• Transaction type/code: A (Grant/Award or other acquisition of a derivative).
• Shares/units: 20,215 underlying shares reported; reported price: $0.00; reported value: $0.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The award vests and becomes exercisable in full on the earlier of (i) June 9, 2027 or (ii) the issuer’s next annual meeting, subject to Fitzgerald’s continued service.
• No indication of a 10b5-1 plan, cashless exercise, gift, or tax-withholding event in this filing.

Context
This is a typical director compensation award (a derivative grant) and does not represent an open-market purchase or sale. Because it vests in the future and becomes exercisable only if the director remains in service (or the company reaches the specified date), it’s primarily a retention/compensation instrument rather than an immediate market commitment.